Vitrolife's Q2 sales came in just below consensus at SEK857m but restructuring delivery drove EBITDA margins ahead of expectations coming in at 34%. The market read the report and buyback positively and the stock screens as "Attractively Priced" at a ~30% discount to Redeye's fair value.
LÄS MER
